中西医结合治疗风湿性关节炎临床研究

Clinical study of combination of traditional Chinese and Western medicine in the treatment of rheumatoid arthritis

目的探讨对风湿性关节炎患者实施中西医结合治疗的疗效与安全性。方法 78例风湿性关节炎患者,按照随机数字表法分为对照组和实验组,各39例。对照组采用常规治疗加用西药洛索洛芬钠,实验组在对照组基础上加用中药附桂骨痛颗粒,对比两组患者的临床治疗效果、关节疼痛指数、肿胀指数、压痛指数及不良反应发生情况。结果实验组治疗总有效率94.87%高于对照组的76.92%,差异具有统计学意义(P<0.05)。两组治疗后关节疼痛指数、肿胀指数、压痛指数均低于治疗前,差异具有统计学意义(P<0.05);治疗后实验组关节疼痛指数、肿胀指数、压痛指数均低于对照组,差异具有统计学意义(P<0.05)。治疗过程中两组均无不良反应发生。结论对风湿性关节炎患者在西药治疗的基础上加用中药附桂骨痛颗粒可显著提高疗效,改善临床症状,并且安全可靠,具有临床推广应用价值。

Objective To discuss the efficacy and safety of combination of traditional Chinese and western medicine in the treatment of patients with rheumatoid arthritis. Methods A total of 78 patients with rheumatoid arthritis were divided by random number table method into control group and experimental group, with 39 cases in each group. The control group received conventional therapy and western medicine loxoprofen sodium, and the experimental group received traditional Chinese medicine Fugui Gutong granules. Comparison were made on clinical treatment effect, joint pain index, swelling index, pressure pain index and occurrence of adverse reactions between two groups. Results The experimental group had higher total treatment effective rate as 94.87% than 76.92% in the control group, and the difference was statistically significant （P〈0.05）. Both groups had lower joint pain index, swelling index and pressure pain index after treatment than before treatment, and their difference was statistically significant （P〈0.05）. The experimental group had lower joint pain index, swelling index and pressure pain index after treatment than the control group, and their difference was statistically significant （P〈0.05）. Both groups had no occurrence of adverse reactions during treatment. Conclusion Application of traditional Chinese medicine Fugui Gutong granules on the basis of western medicine can significantly improve efficacy of patients with rheumatoid arthritiS, and improve clinical symptoms with safety and reliability. It contains clinical promotion and application value.